Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Acceptance and Commitment Therapy for Mesh Injury: A HSCED Series

11 de novembro de 2026 atualizado por: University of Lincoln

The Mesh Scandal: Acceptance and Commitment Therapy for Psychological Distress in Mesh Injured Women. A Hermeneutic Single-Case Efficacy Design Series.

The Patient Safety Commissioner estimates that at least 10,000 women in England have experienced significant harm resulting from vaginal mesh implants. Adverse effects resulting in psychological distress and reduced quality of life have been reported. The purpose of the study is to explore the efficacy of Acceptance and Commitment Therapy (ACT) for women with mesh injury experiencing psychological distress.

The study will use a Hermeneutic Single-Case Efficacy Design to answer the primary and secondary objectives.

Primary objective: To investigate whether ACT is an effective therapeutic intervention for women experiencing psychological distress due to mesh injury.

Secondary objectives: To determine whether there are any meaningful changes throughout the ACT intervention; whether these changes can be attributed to the ACT intervention and what factors contribute to the changes.

Participants will undergo a ten-session ACT intervention and follow-up session. A qualitative interview will be carried out to explore the change experience.

Visão geral do estudo

Descrição detalhada

NICE guidelines recognise the physical and psychological impact of mesh complications and recommends that psychological and psychosexual support is offered to women affected. Despite this, a therapeutic intervention for mesh complications has not yet been explored. Acceptance and Commitment Therapy (ACT) as been empirically supported for its use with populations with long term health conditions.

The study will use a hermeneutic single-case efficacy design and evaluate the process of change during the intervention. Following the ACT intervention, rich case records for each participant will be created using quantitative and qualitative data; this data will consist of demographic data, outcome measures and therapy material. The rich case records will be cross-referenced and amalgamated into an "affirmative" brief that presents evidence that the change can be attributed to the therapeutic intervention. The rich case record will also be analysed for indirect evidence to develop a "skeptic" brief, a brief presenting an alternative explanation for the therapeutic change. Both analyses will be evaluated through a presentation of both briefs, a rebuttal of the opposing brief and a summary narrative . The adjudication process will be overseen by three independent judges who will evaluate the rich case records and briefs to provide an outcome ; whether there has been a change during the therapeutic intervention and whether the therapeutic intervention was a key influence on this outcome.

Tipo de estudo

Intervencional

Inscrição (Estimado)

6

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

Woman aged 18 or over.

  • Registered with a UK GP.
  • Currently under the care of or recently discharged from Nottingham or Manchester Complex Mesh Centres or have contacted their GP about mesh complications.
  • Has had surgery for Stress Urinary Incontinence (SUI) and/or Pelvic Organ Prolapse (POP) and has or have had implanted polypropylene mesh causing complications.
  • Experiencing self-reported psychological distress.
  • Able to communicate in English.
  • Has access to a device with internet access.
  • Willing and able to provide informed consent for participation in the study.
  • Willing to engage in psychological therapy.

Exclusion Criteria:

  • ACT intervention in the past twelve months due to the potential impact on the efficacy of the therapeutic intervention and to reduce cofounding variables.
  • Currently engaging in psychological therapy due to the potential impact on the efficacy of the therapeutic intervention and to reduce cofounding variables.
  • Have insufficient command of the English language due to resources and potential impact of an interpreter on mechanism of change.
  • Significant cognitive impairment.
  • Current suicidal ideation for ethical and safety reasons.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Acceptance and Commitment Therapy

Participants will receive a ten-session Acceptance and Commitment Therapy (ACT) intervention

Acceptance and commitment therapy (ACT) is a "third wave" Cognitive Behavioural Therapy that focuses on increasing psychological flexibility and acceptance of difficult experiences by undertaking value-drive actions despite psychological suffering. Psychological flexibility is developed and expanded through six core processes: acceptance, defusion, present moment awareness, self-as-context, values and committed action.

Adherence to a strict protocol is not mandated for an ACT intervention; the study will be informed by an adapted ACT intervention for chronic pain (Scott et al., 2018). The intervention will reflect the heterogenous nature of mesh injury.

The intervention will consist of ten individual weekly sessions lasting up to 60 minutes.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Hermeneutic Single-Case Efficacy Design - adjudication
Prazo: Through study completion, an average of 9 months.

The adjudication process will be overseen by three independent judges who will evaluate the rich case records and briefs to provide an outcome ; whether there has been a change during the therapeutic intervention and whether the therapeutic intervention was a key influence on this outcome (Elliott et al., 2009).

Through study completion, an average of 9 months.
Psychological distress assessed using the Clinical Outcomes in Route Evaluation 10 (CORE-10; Barkham et al., 2013)
Prazo: From baseline to the end of treatment, up to 16 weeks.

10-item measure designed to measure common presentations of psychological distress. The minimum value is 0 and the maximum value is 40. A higher score indicates severe distress.

From baseline to the end of treatment, up to 16 weeks.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Mesh symptoms impact on quality of life assessed using the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol; Kelleher et al., 1997)
Prazo: From baseline to the end of treatment, up to 16 weeks.

20-item measure designed to measure the physical, emotional, social, and practical impact of urinary symptoms. Measure adapted to assess "mesh problem" instead of "urinary problem" (Brown, 2020). The minimum value is 0 and the maximum value is 76. A higher score indicates greater impact on quality of life.

From baseline to the end of treatment, up to 16 weeks.
Psychological flexibility assessed using the Comprehensive assessment of Acceptance and Commitment Therapy Processes (CompACT-10; Golijani-Moghaddam et al., 2023)
Prazo: From baseline to the end of treatment, up to 16 weeks.

10-item short-form version of the Comprehensive Assessment of Acceptance and Commitment Therapy Processes (CompACT), designed to measure psychological flexibility and its core sub-processes. The minimum value is 0 and the maximum value is 60. A higher score indicates greater level of psychological flexibility.

From baseline to the end of treatment, up to 16 weeks.
Therapeutic alliance assessed using the Session Rating Scale (SRS; Duncan et al., 2003)
Prazo: Weekly during the therapy intervention, up to 10 weeks.

4-item measure designed to measure the quality of the therapeutic alliance. The minimum value is 0 and the maximum value is 40. A higher score indicates greater therapeutic alliance.

Weekly during the therapy intervention, up to 10 weeks.
Client's perception of therapy sessions assessed using the Helpful Aspects of Therapy (HAT; Llewelyn, 1988)
Prazo: Weekly during the therapy intervention, up to 10 weeks.

A measure designed to identify specific events that participants found most helpful during the therapy session. The minimum value is 1 and the maximum value is 9 for each scale. A higher score indicates greater helpful impact.

Weekly during the therapy intervention, up to 10 weeks.
Change in client's goals assessed using the Personal Questionnaire (PQ; Elliott et al., 1999)
Prazo: Weekly during the therapy intervention, up to 10 weeks.

A measure personalised to the participant, identifying problems that the participant would like to work on in therapy. The minimum value is 7 and the maximum value is 91 for each scale. A higher score indicates greater progress towards goals/problem identified at the start of therapy.

Weekly during the therapy intervention, up to 10 weeks.
Adherence to ACT processes measured using the Acceptance and Commitment Therapy Fidelity Measure (ACT-FM; O'Neill et al., 2019)
Prazo: During the therapy intervention for up to 10 weeks.

A measure of therapist fidelity in delivering Acceptance and Commitment Therapy. The minimum value is 0 and the maximum value is 36 for ACT consistent and ACT inconsistent subscales. A higher score for the ACT consistent subscale indicates adherence to ACT processes.

During the therapy intervention for up to 10 weeks.
Client's perception of therapy intervention and change processes assessed using the Client Change Interview (Elliott et al., 2001)
Prazo: Within two weeks of end of therapy intervention, at 12 weeks.

A semi-structured interview to explore the mechanism of change.

Within two weeks of end of therapy intervention, at 12 weeks.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Danielle De Boos, ClinPsyD, University of Nottingham

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de dezembro de 2026

Conclusão Primária (Estimado)

1 de agosto de 2027

Conclusão do estudo (Estimado)

1 de agosto de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

5 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

11 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

The results of the research study will be submitted in partial fulfilment of doctoral thesis in Clinical Psychology. A journal manuscript will be submitted to a peer-reviewed journal and any data submitted will be anonymised. Any published outputs will contain a data availability statement linked to the repository. The full dataset and any special category data will not be publicly available due to participant privacy.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever